Huge thanks to the @awscloud.bsky.social team for the opportunity to participate.

We are excited to continue to showcase how the AI platform capability we’ve built to accelerate and enhance CRISPR therapeutic design also performs at a world-class level on real-world AI challenges.

Thanks, @ahascience.bsky.social, for convening the scientific community to advance cardiovascular research. We were honored to share our latest data at #AHA25.

Check out our press release here: www.businesswire.com/news/home/20...

By engineering #CRISPR-based medicines with durable potency and exceptional specificity, we aim to shift cardiovascular care toward long-term prevention and bring transformative treatments to millions of patients.

Monday 11/10 at #AHA25

3️⃣ In vivo CRISPR technologies for CV Diseases
4️⃣ Single dose of a novel CRISPR-CasX editor potently reduces triglycerides in preclinical models and efficiently edits APOC3 in non-human primates

@ahascience.bsky.social

Saturday 11/8 at #AHA25

1️⃣ STX-1150: A CRISPR-CasX Epigenetic Editor for Durable, Titratable LDLc Lowering
2️⃣ STX-1200: A Novel CRISPR-CasX based Gene Editing Approach for Potent and Selective Reduction of Lipoprotein(a) in Multiple Preclinical Models

@ahascience.bsky.social

Scribe's ELXR platform underpins STX-1150, our #CRISPR-based therapy designed to lower LDL-C and address cardiovascular disease effectively.

Thanks to @marjungle.bsky.social for interviewing our CEO @benjaminloakes.bsky.social and showcasing our innovative ELXR engineering work!

@clarivate.com

At Scribe, we're pioneering custom-engineered CRISPR-based medicines and currently focused on targeting the three core lipid drivers of ASCVD: LDL-C, Lp(a), & triglycerides.

Read about our latest data and progress advancing #CRISPR towards preventing disease ⬇️

www.scribetx.com/news

“...Amazingly, there already are companies, not only academics, but companies that already have that vision and are working on that for cardiovascular disease.”

- Jennifer Doudna, Scribe co-founder, @innovativegenomics.bsky.social founder, Nobel laureate @ #MoSSummit

Dr. Oakes’ leadership is shaping the future of biotech by pioneering Scribe's validated gene and epigenetic editing technologies, strong pharma collaborations, and pipeline aimed at solving leading killers like heart disease.

Read his BioSpace profile 🔽 www.biospace.com/biospace-40-...